Pay in 4 interest-free payments of $7.14 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
TB-500: Around 2.5 mg twice weekly during a loading phase, then roughly once weekly for maintenance
Notably, fosgonimetons Phase 2/3 LIFT-AD trial in mild-to-moderate Alzheimers disease missed its primary endpoint in topline results released in 2023
Research context Published work is dominated by cell and animal models, including studies of VEGFR2-associated signaling and experimental angiogenesis
Key gaps to address: dose-response in humans, safety/tolerability profiles across populations, interaction effects in stacks, and long-term cardiometabolic outcomes
US$ 27.21
US$ 22.74
US$ 24.89
/assets/production/practices/438b59b4e27c5dc64b6d75ab18cf4e16804f233b/images/2831064.png)
US$ 22.87
US$ 20.26
US$ 21.07
US$ 24.64
US$ 20.03
US$ 23.86
